New Insights into the Diagnosis of Pediatric Cholestasis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Diagnosis and Prognosis".

Deadline for manuscript submissions: 31 January 2027 | Viewed by 1778

Special Issue Editor


E-Mail Website
Guest Editor
Pathology Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Interests: liver; liver transplantation; diagnosis

Special Issue Information

Dear Colleagues,

Hyperbilirubinemia occurs in approximately 50% of neonates as an expression of physiological jaundice in the vast majority of cases. Prolonged jaundice (defined as jaundice lasting more than 2 weeks), termed neonatal/infantile cholestasis (NIC), occurs in up to 15% of all neonates and should raise suspicion of cholestasis, prompting further investigation. Rapid etiological definition is of primary importance to initiate appropriate surgical or medical treatment. The broad spectrum of potential causes of NIC requires a complex diagnostic approach that depends on the comprehensive clinical picture. For practical purposes, the causes of cholestasis are divided into surgical (extrahepatic cholestasis) and medical (intrahepatic cholestasis) conditions. The most common surgical cause of NIC is biliary atresia, while medical causes include defects in bile canalicular transport and bile development, inborn errors of bile acid synthesis, and inherited metabolic conditions.

The aim of this Special Issue, titled “New Insights into the Diagnosis of Pediatric Cholestasis”, is to support pediatricians working in primary and secondary care in the initial management of neonatal cholestasis (NIC), alongside pediatric neonatologists and hepatologists working in tertiary referral centers for further diagnostic work-up. We have decided to organize this issue into four sections: the clinical aspect, the surgical approach, diagnostic imaging, and the histological–molecular characteristics of NIC.

Dr. Paola Francalanci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extrahepatic cholestasis
  • intrahepatic cholestasis
  • biliary atresia
  • genetic liver disease
  • inborn errors of metabolism
  • jaundice
  • monogenic liver disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 9845 KB  
Review
Pediatric Cholestasis: A Practical Approach to Histological Diagnosis
by Francesca Arienzo, Silvia Vallese, Isabella Giovannoni, Andrea Pietrobattista, Marco Spada, Rita Alaggio and Paola Francalanci
Diagnostics 2026, 16(6), 878; https://doi.org/10.3390/diagnostics16060878 - 16 Mar 2026
Viewed by 759
Abstract
Pediatric (neonatal and infantile) jaundice resulting from underlying cholestasis (caused by conjugated hyperbilirubinemia) is always pathological and requires prompt evaluation. Pediatric cholestasis can be caused by medical or surgical factors and, if left untreated, can lead to irreversible liver damage. Timely recognition of [...] Read more.
Pediatric (neonatal and infantile) jaundice resulting from underlying cholestasis (caused by conjugated hyperbilirubinemia) is always pathological and requires prompt evaluation. Pediatric cholestasis can be caused by medical or surgical factors and, if left untreated, can lead to irreversible liver damage. Timely recognition of pediatric cholestasis and identification of the underlying etiology are paramount to improve outcomes. The broad spectrum of causes potentially underlying pediatric cholestasis requires a multidisciplinary diagnostic approach, and each aspect must be interpreted in the concomitant clinical picture. A liver biopsy is one component of a complex diagnostic puzzle. However, interpreting a liver biopsy performed on a newborn/infant with conjugated/direct hyperbilirubinemia can be a challenging task, as these biopsies are rarely encountered in general hospitals. The aim of this review is to provide a practical and simplified approach to pediatric cholestasis with examples of real clinical cases we have encountered and discuss key features, both histological and clinical, that can help narrow the differential diagnosis and identify treatable causes. Full article
(This article belongs to the Special Issue New Insights into the Diagnosis of Pediatric Cholestasis)
Show Figures

Figure 1

24 pages, 2972 KB  
Review
Beyond the Pump: The Evolving Molecular Landscape of Intrahepatic Cholestasis
by Ilaria Ziccardi, Michela Zorzi and Adamo Pio d’Adamo
Diagnostics 2026, 16(5), 726; https://doi.org/10.3390/diagnostics16050726 - 28 Feb 2026
Viewed by 747
Abstract
Cholestasis encompasses a broad spectrum of hepatobiliary disorders characterized by impaired bile formation or flow. Historically classified based on clinical onset and severity, the landscape of cholestatic liver disease has been revolutionized by the advent of high-throughput genomic technologies. This review elucidates the [...] Read more.
Cholestasis encompasses a broad spectrum of hepatobiliary disorders characterized by impaired bile formation or flow. Historically classified based on clinical onset and severity, the landscape of cholestatic liver disease has been revolutionized by the advent of high-throughput genomic technologies. This review elucidates the critical role of genetics in redefining the pathophysiology, diagnosis, and management of cholestasis, framing pediatric Progressive Familial Intrahepatic Cholestasis (PFIC) and Adult-Onset Cholestatic Disease (AOCD) as a continuous phenotypic spectrum. We discuss the expansion of the molecular nosology to include 13 distinct PFIC types, highlighting how defects in canalicular transporters, tight junctions, and nuclear receptors underpin clinical heterogeneity. Furthermore, we examine the paradigm shift in the diagnostic flowchart, where Next-Generation Sequencing (NGS) has largely superseded liver biopsy for etiological definition. Finally, we address the therapeutic implications of this molecular precision, demonstrating how specific genotypes dictate eligibility for novel targeted therapies, such as IBAT inhibitors, marking the transition from supportive care to personalized medicine. Full article
(This article belongs to the Special Issue New Insights into the Diagnosis of Pediatric Cholestasis)
Show Figures

Figure 1

Back to TopTop